2023
82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Choo J, Jeraj S, Chan G, Sundar R, Yong W, Lee M, Ngoi N, Wong A, Soo R, Chee C, Lim J, Goh B, Lee S, Tan D. 82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies. Annals Of Oncology 2023, 34: s1498. DOI: 10.1016/j.annonc.2023.10.217.Peer-Reviewed Original Research
2021
40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies
Ho J, Heong V, Yong W, Soo R, Chee C, Wong A, Thian Y, Sundar R, Gopinathan A, Lee S, Goh B, Xu H, Tan D. 40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies. Annals Of Oncology 2021, 32: s17. DOI: 10.1016/j.annonc.2021.01.055.Peer-Reviewed Original Research